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In order to use a Hemoglobin Based Oxygen Carrier as an oxygen therapeutic or blood
substitute, it is necessary to increase the size of the hemoglobin molecule to prevent rapid
renal clearance. A common method uses maleimide PEGylation of sulfhydryls created by
the reaction of 2-iminothiolane at surface lysines. However, this creates highly
heterogenous mixtures of molecules. We recently engineered a hemoglobin with a
single novel, reactive cysteine residue on the surface of the alpha subunit creating a
single PEGylation site (βCys93Ala/αAla19Cys). This enabled homogenous PEGylation by
maleimide-PEG with >80% efficiency and no discernible effect on protein function.
However, maleimide-PEG adducts are subject to deconjugation via retro-Michael
reactions and cross-conjugation to endogenous thiol species in vivo. We therefore
compared our maleimide-PEG adduct with one created using a mono-sulfone-PEG
less susceptible to deconjugation. Mono-sulfone-PEG underwent reaction at
αAla19Cys hemoglobin with > 80% efficiency, although some side reactions were
observed at higher PEG:hemoglobin ratios; the adduct bound oxygen with similar
affinity and cooperativity as wild type hemoglobin. When directly compared to
maleimide-PEG, the mono-sulfone-PEG adduct was significantly more stable when
incubated at 37°C for seven days in the presence of 1 mM reduced glutathione.
Hemoglobin treated with mono-sulfone-PEG retained > 90% of its conjugation,
whereas for maleimide-PEG < 70% of the maleimide-PEG conjugate remained intact.
Although maleimide-PEGylation is certainly stable enough for acute therapeutic use as an
oxygen therapeutic, for pharmaceuticals intended for longer vascular retention (weeks-
months), reagents such as mono-sulfone-PEG may be more appropriate.
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INTRODUCTION
The red blood cell (erythrocyte) provides both volume support
and oxygen transport. Blood loss during trauma and/or pathology
can therefore have serious consequences for the mammalian
vasculature, dropping blood pressure and compromising
oxygen delivery to tissue. Hemoglobin (Hb) is an oxygen
transport protein, present in high concentrations in the
erythrocyte (about 5 mM) and responsible for its oxygen
transport function. When Hb levels drop below a critical level,
the “transfusion trigger” generally between 7 and 9 g/dL, blood
transfusions are recommended to restore these capacities (Yao
et al., 2020). However, even in developed countries with
sophisticated blood banks, systems can become insufficient to
meet the demand in crisis situations (Gniadek et al., 2020); a
condition that is even more critical in developing countries where
it is more challenging to provide a safe supply of red blood cells
(Aneke and Okocha, 2017). Therefore, there has long been a
desire to create artificial “blood substitutes” that could
complement blood transfusion services by providing a long
lasting, stable, pathogen free alternative to blood in critical
care situations (Winslow, 2006). More recently there has been
interest in the development of “oxygen therapeutics”, Hb
solutions designed not to replace blood, but to act in synergy
with erythrocytes to deliver oxygen to tissues difficult for red
blood cells Hb to access (Bettati and Mozzarelli, 2011). Such
oxygen therapeutics have been suggested to play a critical role in
new therapeutic interventions in, for example, stroke, trauma and
sickle cell disease (Kawaguchi, 2017).
By far the most common starting material for a potential blood
substitute or oxygen therapeutic is the Hb molecule, either
purified from outdated human blood, animal blood or
produced using recombinant technology. However, injecting
extracellular Hb alone is ineffective. Although the 64 kDa
tetramer is large enough to remain in the vasculature, outside
the erythrocyte membrane it readily breaks down into dimers
which are rapidly cleared by the kidney (Bunn et al., 1969),
causing oxidative damage in the process (Feola et al., 1990).
Therefore converting Hb into a Hemoglobin-Based Oxygen
carrier (HBOC) requires modifications such as chemical or
genetic cross-linking, conjugation or encapsulation (Bettati and
Mozzarelli, 2011).
The most common conjugation approach used to formulate a
HBOC has been PEGylation with a number of PEGylated Hb
products being tested in vivo. PEGylation of human Hb was used
in previous clinical trials by Sangart [MP4, Hemospan
(Vandegriff and Winslow, 2009)], APEX Pharmaceuticals
[PHP (Vincent et al., 2015)] and Baxter Healthcare [rHb2.0
(Resta et al., 2002)]. Prolong Pharmaceuticals are currently
trialling PEGylated bovine Hb product Sanguinate®
(Abuchowski, 2017) for the treatment of sickle cell disease.
Many of these products used maleimide-PEG conjugation to
create the protein-PEG product. However, due to the scarcity
of reactive cysteine residues in Hb, reagents such as 2-
iminothiolane were used to introduce thiol reactivity at
terminal amino residues and surface lysines in Hemospan
(Vandegriff et al., 2003), Euro-PEG-Hb (Portoro et al., 2008)
and Sanguinate® (Nho et al., 1992). However, this final product is
heterogeneous, due to differences in the efficiency of reaction at
different protein sites both in creating free thiol residues and/or
the subsequent PEGylation at those residues.
The native human Hb α2/β2 tetramer contains six cysteine
residues, each α subunit having one at αCys104 and each β
subunit having two at βCys93 and βCys112. However, by far
the most reactive to chemical modifications is βCys93
(Guidotti and Konigsberg, 1964; Rosemeyer and Huehns,
1967). We recently took advantage of the opportunities
afforded by the use of recombinant Hb as an HBOC
starting material, by replacing βCys93 with alanine and
introducing a novel reactive cysteine residue in the surface
of the α subunit at residue 19. The resultant protein
(βCys93Ala/αAla19Cys) - hereafter named A12 - enabled
efficient homogenous PEGylation at a single protein site
(αAla19Cys) with no deleterious effect on protein function
(Cooper et al., 2020).
In our original paper, we used maleimide-PEG as the
conjugating reagent via Michael addition reactions to the free
cysteine residue (Figure 1A). However, deconjugation via retro-
Michael reactions (Figure 1B) and cross-conjugation to
endogenous thiol bearing species such as albumin and
glutathione have been described for these thiol-maleimide
adducts (Baldwin and Kiick, 2011; Jackson et al., 2014;
Lahnsteiner et al., 2020). In contrast, hydrolytic succinimide
ring opening, also known to occur for maleimide conjugates,
results in a more stable structure less likely to undergo retro-
Michael reaction (Figure 1B).
Enhanced conjugate stability is generally desired by product
developers and significant research efforts have focused on
producing more stable maleimide-based bioconjugates
(Fontaine et al., 2015; Kalia et al., 2017; Ravasco et al.,
2019; Lahnsteiner et al., 2020). Alternatively, mono-sulfone-
PEG reagents (Figure 1A) have been suggested to form more
stable conjugates. As part of the mono-sulfone PEGylation
process, the ketone in the linker is reduced to a secondary
alcohol using sodium borohydride post-conjugation
(Figure 1C). Prior to reduction the α-keto protons are
mildly acidic and can be deprotonated by a base (the first
step of a retro-Michael reaction). In the reduced (stabilized)
linker these protons are non-acidic and electronically the
retro-Michael reaction is a non-viable mechanism of
deconjugation. For example, a reduced mono-sulfone-PEG
conjugate of a laminin-β peptide was shown to be stable
over 12 days at room temperature in a pH 7.5 phosphate
buffer; under the same conditions non-reduced mono-
sulfone-PEG and maleimide-PEG conjugates exhibited
≈20% and ≈40% deconjugation respectively (Badescu et al.,
2014).
Ideally, a HBOC oxygen therapeutic should stay in the
vasculature for up to a week. Loss of conjugation would lead
to rapid renal clearance of Hb dimers. In this study we therefore
compared the efficiency and stability of our previous Hb
PEGylation method using maleimide-PEG (Cooper et al.,
2020), with a potentially more stable conjugation with a
reduced mono-sulfone-PEG.
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MATERIALS AND METHODS
Materials
Recombinant protein production in Escherichia coli and
purification of the Hb mutant termed A12 was as described in
detail previously (Cooper et al., 2020). Essentially, BL21 (DE3)
cells transformed with pETDuet-1 plasmid containing human Hb
with mutant βCys93Ala and αAla19Cys genes were grown in
shake flask cultures. Cells were harvested and the Hb protein
purified by a combination of cation exchange, anion exchange
and affinity chromatography. Samples were stored in liquid
nitrogen as stable carbonmonoxy-ferrous Hb (HbCO) adducts
and converted to different Hb forms when required (Simons et al.,
2018).
20 kDa mono-sulfone-PEG was prepared according to a
published synthetic route (Badescu et al., 2014) and 20 kDa
maleimide-PEG was purchased from Iris Biotech. A 1 M
solution of sodium borohydride, purchased from Sigma-
Aldrich, was prepared in 0.1 M NaOH prior to use. All other
materials for bioconjugation were supplied by Fisher Scientific,
Merck, VWR, GE Healthcare, Sigma-Aldrich and Melford. The
PEGylation buffer (100 mM HEPES, 1.2 mM sodium phosphate,
100 mM NaCl, 1 mM EDTA, pH 7.0) was purged with carbon
monoxide (BOC) before use. For stability studies reduced
glutathione was purchased from Sigma-Aldrich.
Oxygen Binding
Measurements were carried out essentially as described
previously (Cooper et al., 2020) by diluting ferrous oxygenated
Hb in 100 mM HEPES, 100 mM NaCl, 1.2 mM sodium
phosphate, 1 mM EDTA, pH 7.0. The final protein
concentration was 100 μM (heme basis). The oxygen
equilibrium curves were measured at 25°C by deoxygenating
samples using a helium flow and then equilibrating with
different oxygen partial pressures. For each sample, the
absorption spectrum was collected to determine the fractional
Hb oxygen saturation. Sodium ascorbate and catalase were added
to the solution before the titrations to reduce any inactive ferric
FIGURE 1 | Structure and reactivity of PEG conjugation reagents.
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(met) Hb form and limit its formation during the titration. A
titration required about 5 h.
Mono-Sulfone-PEG Hb PEGylation Process
Screening (Figures 2–4)
Hb was maintained in the carboxyhemoglobin form (HbCO) to
prevent oxidation during the PEGylation process. Absorption
spectra were collected in the range of 450–700 nm and the protein
concentration calculated using the molar extinction coefficients
for HbCO (Antonini and Brunori, 1971). Three vials of HbCO
(0.72 mg, 13.2 μL) were adjusted to 1 mM concentration (on
monomer basis) with the CO purged PEGylation buffer
(31.8 μL) at pH 7.0. A stock solution of 20 kDa mono-sulfone-
PEG (10 mM) in CO PEGylation buffer was prepared
immediately prior to use. CO PEGylation buffer and 20 kDa
mono-sulfone-PEG in 12:1, 6:1 and 3:1 PEG:Hb tetramer ratios
were then added to the protein solutions to give final Hb
monomer concentrations of 0.77 mM. PEGylation was then
allowed to proceed at 25°C with timepoints taken at 2, 3, 4
and 5.5 h. Each timepoint sample (13 μL) was diluted with
600 mM sodium phosphate, pH 7.5, 150 mM NaCl, 20 mM
EDTA buffer (13 μL) and the resulting solutions were cooled
in an ice-bath. To the Hb-PEG solutions, 1 M sodium
borohydride (1.2 μL) was added, and the reduction mixtures
were immersed in ice for 30 min. A second portion of 1 M
sodium borohydride (1.2 μL) was added to the reactions and a
further 30 min on ice was allowed. Once all timepoint samples
had been acquired, analysis was performed by SDS-PAGE using
4–12% Bis-Tris gels using published methods (Cooper et al.,
2020).
PEG-Hb Production for Stability
Assessment (Figures 5, 6)
Maleimide-PEG Hb
HbCO (5 mg, 91.6 μL) was adjusted to 1 mM concentration (on
monomer basis) with CO purged PEGylation buffer (221 μL). A
stock solution of 20 kDa maleimide-PEG (10 mM) in CO
PEGylation buffer was prepared immediately prior to use. To
the protein solution was added 20 kDa maleimide-PEG (20.9 mg,
93.8 μL) in 12:1 PEG:Hb tetramer ratio. PEGylation was then
allowed to proceed at 25°C for 2 h. The reaction was quenched by
the addition of 3.13 μL of a 0.9 ML-cysteine solution.
Mono-Sulfone-PEG Hb
HbCO (5 mg, 91.6 μL) was adjusted to 1 mM concentration (on
monomer basis) with CO purged PEGylation buffer (221 μL). A
stock solution of 20 kDa mono-sulfone-PEG (10 mM) in CO
PEGylation buffer was prepared immediately prior to use.
Additional CO PEGylation buffer (70.3 μL) and 20 kDa mono-
sulfone-PEG (5.3 mg, 23.4 μL) in 3:1 PEG:Hb tetramer ratio, were
added to the protein solution. PEGylation was then allowed to
proceed at 25 C for 4 h. The reaction was next diluted with
600 mM sodium phosphate, pH 7.5, 150 mM NaCl, 20 mM
EDTA buffer (406 μL) and the resulting solution was cooled in
an ice-bath. To the Hb-PEG solution, 1 M sodium borohydride
(9.38 μL) was added, and the reduction mixture was immersed in
ice for 30 min. A second portion of 1 M sodium borohydride
(9.38 μL) was added to the reaction and a further 30 min on ice
was allowed.
Hb-PEG Purification
Unreacted reagents and unmodified Hb were removed by
ultrafiltration/diafiltration (UF/DF) against CO purged PBS
using centrifugal filters fitted with 100 kDa MWCO PES
membranes. Red permeates were observed due to the presence
of unmodified and/or monoPEG Hb. After UF/DF, absorption
spectra were collected to check concentration and oxidation state.
The samples were then frozen and stored at −80°C.
Hb-PEG Stability in PBS Containing 1mM Reduced
Glutathione (GSH)
Hb-PEG solutions were prepared at 0.5 mg/mL in CO purged
PBS buffers containing no additive or 1 mM reduced GSH. Each
sample was supplemented with 0.05% w/v sodium azide. Aliquots
(60 μL) of the samples were then prepared. One aliquot per
sample was directly frozen at −80°C (t  0 days). The
remaining aliquots were incubated at 37°C. At t  1, 3 and
7 days samples were removed from storage at 37°C and frozen
at −80 °C. Once all timepoint samples had been acquired, the
samples were thawed and analyzed by SDS-PAGE using 4–12%
Bis-Tris gels as previously described (Cooper et al., 2020).
Data Processing Methodology
The stabilities of maleimide- and mono-sulfone PEG Hb
conjugate linkages were assessed by evaluating the levels of the
Hb-PEG and free Hb bands observed by SDS-PAGE gel band
densities in isolation (i.e., ignoring all other species present). For
normalization and to aid comparison, the percentage of Hb-PEG
was expressed as a relative percentage compared to the t  0 days
value in each analysis.
RESULTS
In the recombinant human Hb mutant studied (A12), the
βCys93Ala mutation removes the only native reactive cysteine
in Hb on the β subunit near the α/β interface and the αAla19Cys
mutation creates a new reactive cysteine on the α subunit. This
new cysteine is at a surface site distant from the dimer/dimer
interface and heme pocket, and hence less likely to affect protein
function than βCys93.
Figure 2 shows SDS-PAGE gels of unmodified A12 and A12
following treatments with different amounts of a mono-sulfone
PEG for different durations. SDS separates the 4 non-covalently
bound subunits of A12 (α2β2) into 16 kDa α and βmonomers. A
small fraction of A12 runs as a covalently bonded dimer,
presumably either due to oxidative deamination and
intramolecular cross-linking during expression in E. coli
(Levine et al., 1998) or a new disulfide bridge between the
αAla19Cys residues in the two dimers (Cooper et al., 2020)
Following PEGylation with 20 kDa mono-sulfone PEG, a
significant new band is observed at 56 kDa and smaller bands
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at ca. 70 and 100 kDa, and - at high PEG:Hb ratios - bands
>150 kDa. Given that PEGylated Hb adducts run at higher
apparent molecular weight than predicted from unPEGylated
protein markers (Caccia et al., 2009), the 56 kDa band is
consistent with mono-PEGylation of A12 at Ala19Cys as was
previously seen following maleimide-PEGylation (Cooper et al.,
2020). The band at 70 kDa is likely mono-PEGylated Hb dimer
and the 100 kDa band is consistent with di-PEGylated Hb
monomer, with non-specific PEGylation at a second site
evident. The bands >150 kDa presumably represent additional
non-specific PEGylation sites only populated at PEG:Hb ratios
>6:1.
As the denaturing gel separates the Hb α2β2 tetramer into α
and β monomers, Hb with 100% mono-sulfone PEG attachment
to the two αAla19Cys subunits will run as two bands of equal
density: the 16 kDa band of the two unPEGylated β monomers
and the 56 kDa band of the two PEGylated α monomers.
Consistent with this an approximate 50:50 ratio between the
protein intensity at the 16 kDa and 56 kDa bands is indeed seen at
PEG:Hb ratios from 3–12 and incubation durations from 2–5.5 h.
The longer the incubation time and the higher PEG:Hb ratio, the
closer the ratio comes to 50:50. However, this is at the expense of a
significant increase in the fraction of Hb that is PEGylated at
multiple sites. Therefore for future studies a compromise was
chosen of an incubation at 3:1 PEG:Hb ratio for 4 h, leading as it
does to >80% yield of the desired mono PEGylated product with
less than 2.5% di-PEGylation.
Figure 3 shows the oxygen binding curve for mono-sulfone
PEG A12. Under “pseudophysiological” conditions (see
Methods), the oxygen affinity was 4.82 ± 0.32 Torr with a Hill
coefficient for cooperative oxygen binding of 1.7 ± 0.2. This is
broadly in line with recombinant Hb for this mutant measured
under the same conditions, with or without maleimide-
PEGylation (Cooper et al., 2020). This indicates that, like
maleimide-PEG, the mono-sulfone-PEG conjugate of A12 has
no dramatic effect on the functional properties of the protein.
Figure 4 directly compares the efficiency of A12 PEGylation
with maleimide-PEG or mono-sulfone-PEG. Both PEG reagents
behave similarly although the mono-sulfone-PEG does show a
FIGURE 2 | SDS-PAGE of Hb A12 following incubation with mono-sulfone PEG. Gels illustrated before (A12) and after PEGylation with mono-sulfone PEG at
different PEG:Hb ratios for different durations of incubation. M molecular weight markers. Labels equate to % of total protein in lane in each band for: Di-PEGylated Hb
monomer; Mono-PEGylated Hb Monomer; Hb dimer; Hb monomer. Enclosed rectangle illustrates conditions chosen for later studies.
FIGURE 3 | Oxygen equilibrium binding curves. Y represents fractional
binding as a function of oxygen partial pressure. Values for binding affinity
(p50) and cooperativity (n) are presented ±SEM of the nonlinear regression
curve fit to the Hill equation. For experimental conditions see Materials
and Methods.
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significant fraction of di-PEGylated product. A brief
incubation with competing thiol (dithiothreitol, DTT) at
40°C reduced some of the covalent dimers in the A12
starting material, most likely by breaking interdimer
disulfide bridges. However, this incubation at 40°C also
seemed to partially degrade the maleimide-PEG product.
Therefore a longer term stability study at physiological
temperatures was performed in the presence and absence of
GSH (Figure 5). Both maleimide-PEG and mono-sulfone-PEG
conjugates showed good stability following incubation in
phosphate buffered saline (PBS) for seven days at 37°C,
with very little (< 5%) decrease in the mono-PEGylated
product. However, in the presence of 1 mM GSH, PEG
deconjugation was faster. Figure 6 shows a side-by-side
comparison of the stability of A12 Hb-maleimide-PEG and
A12 Hb-mono-sulfone-PEG over the seven-day period. In the
mono-sulfone-PEG A12 the loss was < 10% even in the
presence of a competing thiol. In contrast, in maleimide-
PEG A12 there was greater deconjugation, with a >30% loss
in PEGylation after seven days in the presence of GSH.
FIGURE 4 | SDS-PAGE comparing A12 conjugation with maleimide-PEG and mono-sulfone PEG. Novex MW markers (M); Hb-A12 (1); Hb-A12 + 10 mM DTT
40°C 1 h incubation (2); maleimide-PEG-A12 reaction mixture (3); maleimide-PEG-A12 product (4); maleimide-PEG-A12 product +10 mM DTT 40°C + 1 h (5); mono-
sulfone PEG-A12 reaction mixture (6); mono-sulfone PEG-A12 product (7); mono-sulfone PEG-A12 product +10 mM DTT 40°C + 1 h incubation (8). Stoichiometry for
incubation: maleimide-PEG: Hb  12:1; mono-sulfone-PEG: Hb  3:1. Labels equate to % of total protein in lane in each band for: Di-PEGylated Hb monomer;
Mono-PEGylated Hb Monomer; Hb dimer; Hb monomer.
FIGURE 5 | Effect of GSH on stability of Hb-PEG conjugates. SDS-PAGE comparing stability of A12 conjugation with maleimide-PEG and mono-sulfone PEG
following incubation for 7 days at 37°Cwith PBS or 1 mMGSH. Labels equate to%of total protein in lane in each band for: Di-PEGylated Hbmonomer; Mono-PEGylated
Hb Monomer; Hb dimer; Hb monomer.
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DISCUSSION
Specificity of Conjugation Reaction
This paper demonstrates that it is possible to engineer a new
sulfhydryl residue on the surface of a clinically relevant protein
(Hb) that can be conjugated efficiently by two different methods.
The genetically engineered cysteine residue that replaced
Alanine19 on the Hb α subunit, resulted in >85% mono PEG
product using either maleimide-PEG or mono-sulfone PEG
(Figure 5). However, there were some differences between the
two methods. The mono-sulfone Hb had considerable cross-
reactivity at other sites if used at the same concentration ratio as
maleimide-PEG (12:1 PEG:Hb ratio). In the worst-case scenario
(12:1 PEG:Hb ratio for 5.5 h) almost 1/3 of the PEGylated protein
was conjugated at more than one site per Hb dimer, resulting in a
significant fraction of di (and higher) PEGylated products
(Figure 2). This reactivity must be at a different Hb residues
to the cysteine engineered at the α19 residue.
Of the three cysteine residues in native human Hb, the surface
accessible βCys93 is readily reactive to sulfhydryl reagents, such
as iodoacetamide (Guidotti and Konigsberg, 1964) or
p-hydroxymercuribenzoic acid (PMB) (Rosemeyer and
Huehns, 1967). As the concentration of PMB is increased,
further modification can occur, first at αCys104 and then at
βCys112 (Kan et al., 2013). Our A12 recombinant Hb contains
the βCys93Ala mutation so PEGylation at βCys93 cannot occur
and PEGylation is at first favoured at the newly introduced
surface site αAla19Cys (Cooper et al., 2020). It is possible that
higher concentrations of mono-sulfone-PEG are increasingly able
to modify the more inaccessible αCys104 and the βCys112
residues, resulting in higher order PEG species.
As Hb runs as a monomer on a denaturing gel - and A12 has
two cysteine on its α subunit and one on its β subunit - the highest
order PEGylation observed on a denaturing gel for the reaction
of mono-sulfone-PEG solely at A12 cysteines would be di-
PEGylation (at αCys19 and αCys104). Yet at high PEG:Hb
ratios, a tri-PEGylated species is clearly observed (Figure 2).
This requires PEGylation at a different site than cysteine. Given
the almost complete absence of higher order species following
conjugation with maleimide-PEG (Figure 4), this site is likely to
be one that is both surface accessible and available for preferable
conjugation by mono-sulfone PEG over maleimide-PEG. At
neutral pH, maleimide-PEG is far more reactive at sulfhydryl
than other nucleophilic residues such as amines. However, this is
less true for mono-sulfone PEG; indeed bis-sulfone-PEGs similar
to those described in this paper have been shown to react with
polyhistidine tags in proteins (Cong et al., 2012). Of the potential
surface primary amines or histidine on Hb, of note are the
significant number of reactive lysine residues. These were
taken advantage of in the PEGylation method developed by
Sangart Inc. for their oxygen therapeutic Hemospan (MP4,
MalPEG-Hb), which involved reaction at surface lysine
residues by 2-iminothiolane, followed by conjugation of the
resulting thiols using maleimide-PEG (Vandegriff et al., 2008).
Ten surface lysine residues were found to be reactive to 2-
iminothiolane; three on the α subunit (αLys7, αLys16, and
αLys40) and seven on the β subunit (βLys8, βLys17, βLys59,
βLys66, βLys95, and βLys132). It is therefore reasonable to
assume that at least some of the higher order di- and tri-
PEGylated species observed involve conjugation of mono-
sulfone-PEG to one of these surface lysines.
One option to decrease the formation of these higher order
conjugates would be to remove the reactive cysteine and/or amine
residues by site directed mutagenesis, always assuming of course
that protein function is conserved. In terms of cysteines, βCys112
is situated near the α/β interface. However, it is not highly
conserved in mammalian Hbs and replacing βCys112 with
glycine has minimal effects on protein structure and function
(Vasquez et al., 1999). Although the β112 Asp, Ser, Thr or Val
mutations do result in proteins with differences in the dimer/
tetramer equilibrium, they still retain largely unchanged oxygen
transport properties (Yamaguchi et al., 1998). Databases of
human Hb polymorphisms reveal some protein instability in
Hb from people with βCys112 mutations (Giardine et al., 2020).
However, whilst βCys112Arg (Hb Indianapolis) is linked to
thalassemia (Adams et al., 1979), there are few, or no, clinical
symptoms for people with βCys112Gly (Hb Saint-Marcelin),
βCys112Phe [Hb Canterbury, (Brennan et al., 2002)],
βCys112Tyr [Hb Yahata, (Harano et al., 1991)] and
βCys112Trp [Hb Toranomon, (Harano et al., 1996)].
Therefore, it seems entirely feasible to substitute the βCys112
residue using recombinant techniques, if it were deemed
important to decrease further non-specific PEGylation
reactions in a clinical product. An alternative to removing
βCys112 in adult Hb is to use the strongly homologous fetal
FIGURE 6 | Kinetics of stability of A12 Hb-PEG conjugates. Graphs
show the % drop in Hb PEGylation (assuming 100% PEGylation at t  0).
Curve fits illustrated are mono exponential decay for the maleimide-PEG
species. The mono-sulfone-PEG curve fits superimpose on the
maleimide-PEG + PBS fit so have been removed for clarity. Legend: + PBS
maleimide-PEG (o); + PBS mono-sulfone-PEG (□); + 1 mM GSH maleimide-
PEG (C), + 1 mM GSH mono-sulfone PEG (■).
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Hb (HbF), as starting material (Ratanasopa et al., 2015; Simons
et al., 2018). HbF is an α2γ2 tetramer; the γ subunit of HbF has no
cysteines other than γCys93, making the mutant γCys93Ala
completely unreactive to sulfhydryl reagents.
In contrast to βCys112Phe, αCys104 is highly conserved across
many Hb species and might be more difficult to replace. Clinical
data support this (Giardine et al., 2020). The Hb chain in humans
is coded for in two almost identical genes (HbA1 and HbA2).
Hemoglobin polymorphisms reveal severe protein instability in
Hb from people with Cys104 mutations in their HbA1 or HbA2
genes. Reported mutations include HbA2 αCys104Arg [Hb
Iberia, (Bento et al., 2012)], HbA2 αCys104Tyr [Hb
Sallanches, (Morle et al., 1995)], HbA1 αCys104Ser [Hb
Oegstgeest, (Harteveld et al., 2005)] and HbA1 αCys104Trp
(alpha codon 10 TGC-TGG). In these cases, the protein is too
unstable to be detectable in heterozygotes or associated with
thalassemia in homozygotes.
In general αCys104 is the most inaccessible of the three
cysteines in adult Hb to chemical modification with the least
solvent accessible surface area (Mitra et al., 2017). Even when it is
somewhat more accessible than βCys112 to modification [e.g. by
PMB (Kan et al., 2013)], this is likely due to structural changes in
Hb produced by PMB first reacting at βCys93 facilitating
dissociation of the α/β dimer into monomers (Rosemeyer and
Huehns, 1967). As a result, αCys104 is likely to remain
inaccessible to PEGylation in Hb mutants such as A12, which
lack βCys93. Therefore even if it were possible to produce a stable
mutated protein, it would likely not be advantageous to mutate
this residue to decrease non-specific PEGylation reactions.
Any side reactions due to conjugation by mono-sulfone-PEG
at surface amines would be harder to alter by site directed
mutagenesis, given the larger number of potentially reactive
sites (including at least ten lysines as previously noted). A first
step would be to address the scale of the problem by identifying
the specific lysines modifiable by mono-sulfone-PEG (Iafelice
et al., 2007; Vandegriff et al., 2008) and then determining if they
were essential to protein function. However, a more practical
solution is likely to be to optimize the incubation conditions.
Lowering the PEG:Hb ratio and shortening the incubation time
decreased the ratio of diPEGylated Hb to monoPEGylated Hb to
approximately 5% (Figure 2). Fine tuning of the PEGylation
condition could decrease these side reactions even further
(Badescu et al., 2014). One option is to lower of the pH in the
incubation medium below the current 7.0; this could increase the
specificity of the sulfhydral reactivity of the mono-sulfone PEG by
suppressing reactivity with amino groups.
Stability of Conjugation Product
The two PEGylation methods differed significantly in terms of
stability of the mono-PEGylated form in the presence of a
competing thiol (Figure 6). The mono-sulfone PEG was
resistant to deconjugation for seven days at 37°C, retaining
over 95% conjugation in the presence of both PBS and 1 mM
GSH. In contrast the maleimide-PEG form of A12 retained only
about 70% conjugation after incubation with 1 mM GSH. In all
cases the maleimide-PEG deconjugation approached a minimum
after seven days with a significant fraction of protein conjugate
still intact; it is possible that that during the incubation period, a
sub-portion of the maleimide-PEG conjugate undergoes
hydrolytic ring opening, contributing to the stability observed.
In this study we have clearly shown that mono-sulfone PEG
provides an efficient conjugate that is more stable than
maleimide-PEG. Alternative conjugate stabilization methods
are available. The maleimide-PEG bond itself can be stabilised
if the succinimide moiety of a maleimide−thiol conjugate is
hydrolyzed, as the ring-opened product is resistant toward
cleavage (Fontaine et al., 2015); thiomaleimides can be
stabilized by light-triggered ring hydrolysis (Kalia et al., 2017)
and the thiosuccinimide by transcyclization reactions
(Lahnsteiner et al., 2020). As well as mono-sulfone PEG,
alternatives to maleimide-PEG as the conjugate starting
material include exocyclic maleimides (Kalia et al., 2016), and
carbonylacrylic reagents (Bernardim et al., 2016). Also 2-
formylphenylboronic acids (Li et al., 2020) provide stable
alternatives compared to maleimide-PEG.
The relative stability results in our paper are in broad
agreement with a previous study comparing mono-sulfone-
PEG and maleimide-PEG conjugation to a single cysteine
residue on Lamβ925−933, a synthetic linear nona-peptide
corresponding to residues 925–933 of the laminin β1 chain
(Badescu et al., 2014). In that study, there was no
deconjugation of the mono-sulfone-PEG adduct over a twelve-
day incubation period. However, there was 40% deconjugation of
the maleimide-PEG adduct, with most of that occurring in the
first three days. The work reported in the current paper is more
significant, however. The Lamβ925−933 stability study was at room
temperature in pH 7.5 phosphate buffer. However, Figure 6
shows that a mono-sulfone PEG adduct to a full length
physiologically relevant protein (Hb) shows minimal
deconjugation at a physiological ionic strength (PBS) and
physiological temperature (37 °C), even in the presence of
competing thiols at higher than physiological (1 mM GSH)
concentrations.
Physiological Relevance of Enhanced
Stability of the Conjugate
How relevant is the enhanced stability these alternative
PEGylation methods provide compared to the more common
maleimide-PEGmethod? For drug conjugates requiring relatively
short in vivo lifetimes, the lifetime of the thioether conjugate bond
formed using maleimide-PEG frequently exceeds the desired in
vivo lifetime of the drug conjugate. However, when the desired
lifetime of the drug is weeks to months, as in some antibody drug
conjugates, thiol exchange rates can exceed their intended in vivo
lifetime resulting in the premature loss of active drug and/or the
formation of a toxic unconjugated drug (Shen et al., 2012).
What is the lifetime for Hb when formulated as an oxygen
therapeutic? In normal physiological situations, Hb is packed
inside red blood cells and shares the lifetime of those cells, with a
mean of 115 days (Franco, 2012). However, outside the red blood
cell this lifetime is considerably shorter; when infused, cell free Hb
has a limited lifetime of ∼0.5–1.5 h (Savitsky et al., 1978). This is
due to the dissociation of Hb into dimers. These can readily pass
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through the kidney glomerular filtration barrier causing
hemoglobinuria (Savitsky et al., 1978), or be scavenged by the
monocyte/macrophage CD163 receptor - either directly or
following binding to the acute phase protein haptoglobin -
enabling subsequent removal from the circulation by the liver
or spleen (Schaer et al., 2006). A major goal of any HBOC is
therefore to increase the size of Hb and increase vascular
retention. This goal has been achieved in covalently cross-
linked Hb, polymerized Hb, vesicular encapsulated Hb and
PEGylated Hb (Bettati and Mozzarelli, 2011). However, in the
case of historical and current HBOCs the in vivo lifetime in
patients and animal models appears unconnected to the method
of HBOC production. For example studies in patients indicate
half-lives of 3–24 h for cross-linked Hb, 8.5–22 h for polymerized
Hb and 14–66 h for PEGylated Hb (Taguchi et al., 2017). Hb
vesicles have not been infused in humans, although the prediction
from animal models is that the half-life would be of the same
order of magnitude, i.e. no more than three days (Sou et al., 2005).
The similarity of vascular half-life independent of HBOC
production method suggests that the strategy of increasing the
size of the Hb dimer to prevent renal filtration is largely irrelevant
to in vivo lifetime; HBOCs are cleared via the spleen and liver and
not just the kidney (Keipert et al., 1994). This suggests that
PEGylated HBOCs are cleared primarily by phagocytosis
rather than by filtration in the kidney following loss of
conjugation. It therefore seems unnecessary to develop an
alternative to maleimide-PEG for the current use of HBOC as
an oxygen therapeutic targeted for acute use.
However, red blood cells are not just transfused in acute
situations. Although in high-income countries, transfusion is
commonly used for cardiovascular surgery, transplant surgery
and trauma, a significant fraction (>50%) is used in tumor
therapy and for the treatment of blood diseases (Tinegate
et al., 2016). Also, although rarely used to treat anemia in
higher income countries, this is one of the most common uses
of transfusions in lower and middle income countries, especially
in children (Maitland et al., 2019). The use of HBOC in these
non-acute situations would require a significantly longer lasting
HBOC, closer to the vascular lifetime of a red blood cell. The
creation of a more stable PEG conjugation might then become
relevant as part of a strategy to create a long lasting red blood cell
substitute. In that scenario, the enhanced stability of the mono-
sulfone PEG linkage demonstrated in this paper could become an
important part of the solution.
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